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Abstract Examining for new BC biomarkers has proven
that kallikrein-related peptidase (KLK) family members
represent promising serum and/or tissue molecular tools for
early diagnosis, effective prognosis, and treatment moni-
toring of patients. The aim of this study was to investigate,
the previously unexplored, prognostic significance of
KLK8 in BC. KLK8 mRNA expression was quantitatively
analyzed in 150 cancerous and 100 corresponding normal
breast tissue specimens via a SYBR Green-based Real-
Time PCR methodology. Expression data and patients’
clinicopathological parameters were used for extensive
biostatistical analyses, including internal validation. KLK8
mRNA expression was significantly downregulated in the
cancerous tissue part relative to the non-cancerous coun-
terpart (P\ 0.001), in the majority of the paired breast
tissue samples. KLK8 expression was associated with
advanced TNM stage (P = 0.019) and positive nodal status
involvement (P = 0.044). Triple negative (TNBC) and
HER2 overexpressing tumors exhibited higher KLK8
expression levels (P\ 0.001), compared to Luminal A and
B molecular subtypes. Kaplan–Meier survival curve anal-
ysis revealed that BC patients with high KLK8 expression
had significantly shorter disease-free survival (DFS)
intervals (P\ 0.001) compared to those belonging in the
KLK8-low expression group. Cox univariate analysis con-
firmed the association between KLK8 expression, analyzed
as a continuous variable, and poor patients’ outcome
(Hazard ratio [HR] = 3.28, P\ 0.001). Most importantly,
multivariate analysis showed that KLK8 expression is a
strong and independent predictor of adverse DFS in BC
([HR] = 2.74; P = 0.002). Our results show that KLK8
mRNA expression is associated with aggressive tumor
characteristics and it can serve as a novel independent
biomarker of unfavorable prognosis for BC patients.
Keywords KLK8  Kallikreins  Biological tumor marker 
Prognostic biomarker
Abbreviations
AUC Area under the curve
BC Breast cancer
CI Confidence interval
Ct Threshold cycle
DFS Disease-free survival
ECM Extracellular matrix
EMT Epithelial to mesenchymal transition
ER Estrogen receptor
HER2 Human epidermal growth factor receptor 2
HPRT1 Hypoxanthine phosphoribosyltransferase 1
IHC Immunohistochemistry
KLK Kallikrein-related peptidase
MMPs Matrix metalloproteinases
PR Progesterone receptor
ROC Receiver operating characteristic
RQ units Relative quantification units
RT-qPCR Quantitative real-time PCR
TNBC Triple negative breast cancer
TNM Tumor-node-metastasis
Electronic supplementary material The online version of this
article (doi:10.1007/s10549-015-3470-8) contains supplementary
material, which is available to authorized users.
& Andreas Scorilas
ascorilas@biol.uoa.gr
1 Department of Biochemistry and Molecular Biology,
University of Athens, Panepistimiopolis, 15701 Athens,
Greece
2 First Department of Oncology, St. Savvas Anticancer
Hospital, 171, Alexandras Avenue, 11522 Athens, Greece
123
Breast Cancer Res Treat (2015) 152:323–336
DOI 10.1007/s10549-015-3470-8
Introduction
One of the major hurdles in improving breast cancer (BC)
patients’ management is the remarkable molecular and
biological heterogeneous nature of the disease, which in
turn results in distinct clinical presentations and behaviors
of the tumors [1]. Although the routinely used clinico-
pathological factors of prognosis in BC, such as histolog-
ical stage and grade, steroid hormonal receptors’ (estrogen
(ER) and progesterone (PR) receptors), and human epi-
dermal growth factor receptor 2 (HER2) status, are highly
useful [2], it is now apparent that these parameters have a
limited capacity to predict the intrinsic complexity of BC
and to tailor individual treatment [1]. Therefore, contem-
porary research efforts are focused towards the identifica-
tion of novel and more reliable BC-specific biomarkers
which can be found among the biomolecules that play key
roles in fundamental processes underlying cancer estab-
lishment and progression, including members of the family
of kallikrein-related peptidases (KLKs).
Kallikrein-related peptidases (KLKs) are fifteen closely
related secreted serine proteases, which are expressed in a
broad spectrum of human tissues and are involved in a ple-
thora of physiological activities [3–5]. Many studies provide
evidence that the deregulatedKLKexpression and/or function
is a common event in human malignancies [6, 7] and notably,
BC development and KLKs are closely related as well. In
particular, KLK3, KLK6, and KLK10 display tumor sup-
pressive characteristics, whereas KLK1 and KLK11 exhibit
tumor promoting effects during BC progression [6, 8–12].
The KLK8 gene, which maps to the human kallikrein
multigene cluster, encodes for serine protease with trypsin-
like activity [13]. Several experimental data propose dis-
tinct mechanisms, by which KLK8 participates in tumor
progression. Rajapakse et al. showed that KLK8 can effi-
ciently degrade a number of ECM proteins such as collagen
type IV and fibronectin, and thereby facilitates pericellular
proteolysis and cancer cell invasion. The same study also
revealed that KLK8 is able to activate single-chain tissue-
type plasminogen activator (tPA), which in turn generates
plasmin from plasminogen. Plasmin also plays an impor-
tant role in ECM remodeling, either directly through its
own activity or indirectly via the activation of MMPs [13].
Contrariwise, Sher et al. demonstrated that overexpression
of KLK8 suppresses the invasiveness of lung adenocarci-
noma cells in vitro and inhibits tumor growth and invasion
in vivo. This finding was attributed to the degradation of
fibronectin by KLK8, which interferes with the fibronectin-
integrin signaling pathway and reduces tumor cell motility
by preventing actin polymerization [14].
KLKs are being actively investigated for their clinical
value as molecular tumor markers [15, 16] and KLK8 has
been proposed as a promising prognostic biomarker for
ovarian [17–19] and lung cancer [14, 20]. Although previ-
ous studies have revealed that KLK8, like most of the KLK
genes, is downregulated in BC compared with non-
cancerous breast tissues [21, 22], no data have been reported
concerning its possible prognostic importance in BC.
Therefore, the aim of this study was the comprehensive
mRNA expression analysis of KLK8 in breast tumors and
adjacent non-cancerous breast tissues and the investigation
of its previously unexplored, clinical usefulness and prog-
nostic significance as a novel molecular tissue biomarker
for BC.
Materials and methods
Collection of breast tissue samples and clinical data
A total of 150 breast tumor specimens and 100 matched
non-malignant breast tissue sections were collected during
routine therapeutic surgery of patients with newly diag-
nosed BC, at the ‘‘Saint Savvas’’ Anticancer Hospital of
Athens, between 2010 and 2011. Immediately after resec-
tion, each malignant and corresponding normal breast tissue
sample was histopathologically characterized and stored at
-80 C until use. This study was designed according to
new guidelines for reporting new tumor biomarkers [23]
and it was approved by the institutional review board of
‘‘Saint Savvas’’ Anticancer Hospital. Research procedures
of this study complied with the ethical standards of the
World Medical Association’s Declaration of Helsinki. All
participants provided written informed consent prior to
breast tissue harvesting. None of the patients had received
pre-operative (neoadjuvant) treatment.
Patient characteristics and tumor clinical and histopatho-
logical features were also provided for statistical analyses.
Tumors were staged according to tumor-node-metastasis
(TNM) classification and graded based on the Bloom–Scarff–
Richardson grading system (Supplementary Table S1).
Adjuvant systemic treatment was administered to BC
patients according to the guidelines of ‘‘Saint Savvas’’ Anti-
cancer Hospital and the respective consensus recommenda-
tions at the time. In particular, 28 (18.7 %) patients were
treated with endocrine therapy alone; 43 (28.7 %) patients
were given chemotherapy alone; 48 (32.0 %) patients had a
combination of chemotherapy and endocrine therapy, and 19
(12.7 %) patients underwent adjuvant treatment with HER2-
targeted therapy in addition to chemotherapy. Different
treatments are shown in Supplementary Table 1.
BC-specific disease-free survival (DFS) information
were available for 124 patients. DFS was defined as the
time interval between the surgical resection of the tumor
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and the date of the first documented event of either local or
regional recurrence, second cancer, or death from BC, and
was used as an endpoint in the statistical survival analyses
[24]. Table 1 summarizes clinicopathological information
of the samples and patients’ characteristics.
Immunohistochemical (IHC) assessment of hormone
receptors’ expression, HER2 status, and Ki67
labeling index
The expression of ER, PR, HER2, and Ki-67 labeling index
in BC tissue samples was determined by IHC staining in
the pathology laboratory of ‘‘Saint Savvas’’ Anticancer
Hospital. The antibodies used were for ER (Dako 1D5), PR
(Dako PgR636), HER2 (Dako polyclonal rabbit anti-hu-
man c-erbB2), and Ki67 (Dako MIB1).
ER and PR were scored semiquantitatively on the basis
of both the staining intensity (i) and the corresponding
percentage of positive-stained cells (Pi), using the equation
Hscore = R (Pi 9 i/100). The cutoff for positivity of
Hscore was 0.35 for ER and 0.25 for PR. HER2 expression
was initially analyzed by IHC and the intensity of mem-
brane protein staining scores were defined as following: 0,
no staining; 1?, incomplete, weak membrane staining in
[10 % of tumor cells; 2?, weak complete membrane
staining in[10 % of tumor cells; and 3?, intense complete
membrane staining in [10 % of tumor cells. HER2
expression status was considered negative if immunos-
taining was scored as 0 or ?1, and positive if immunos-
taining was scored as ?3. For an equivocal HER2 IHC
(2?) test result, HER2 expression status was considered
positive if fluorescent in situ hybridization (FISH) assay
revealed a HER2: chromosome-17 amplification ratio of
[2.2 [25]. For the nuclear antigen Ki67, the percentage of
positively stained nuclei was calculated. The cutoff value
for Ki67 labeling index was considered as 14 % of positive
cancer nuclei, in order to distinguish tumors with low
(\14 %) and high (C14 %) proliferative fraction [26].
Furthermore, according to the St. Gallen expert con-
sensus, breast tumors can be classified into distinct
molecular subtypes based on IHC staining results for
estrogen and progesterone receptor status, IHC or in situ
hybridization tests for the detection of overexpression and/
or amplification HER2 and Ki67 labeling index. Therefore,
the above-mentioned assessments were used to categorize
breast tumors into: luminal A (ER? and/or PR?, Ki67
low and HER2-), luminal B (ER? and/or PR?, Ki67 high
and/or HER2?), HER2-overexpressing (ER-, PR- and
HER2?), and triple negative (ER-, PR-, and HER2-)
subtypes [1, 26].
Total RNA extraction, RNA quality evaluation,
and cDNA synthesis
Approximately 50–100 mg of each deep-frozen breast
sample, were pulverized to a fine powder and homogenized
by the addition of 1 mL of TRI reagent (Molecular
Research Center). Following the manufacturer’s instruc-
tions, total RNA was extracted, diluted in RNA Storage
Solution (Applied Biosystems), and stored in -80 C. For
all samples, total RNA purity and concentration were
determined spectrophotometrically and RNA integrity was
visually confirmed using agarose gel electrophoresis. Sin-
gle-stranded cDNA synthesis was performed from 2 lg of
total RNA, using M-MuLV reverse transcriptase (Invitro-
gen), recombinant RNase inhibitor (Invitrogen), and oligo
(dT)18 primer, in a final reaction volume of 20 lL.
Table 1 Descriptive statistics
of continuous variables of the
study in breast cancer patients
Variable No. of
patients
Mean ± SEa Range Percentiles
25th 50th (median) 75th
KLK8 (RQ units)
Cancerous tissuesb 150 9.8 ± 2.0 0.009–171.8 0.8 2.5 6.4
Non-cancerous tissuesb 100 11.5 ± 1.4 0.01–89.8 3.2 7.7 12.9
Patients’ age (years) 149 58.7 ± 1.1 31.0–89.0 48.0 59.0 71.0
Tumor size (cm) 139 2.8 ± 0.1 0.8–10.0 1.8 2.5 3.1
Ki67 labeling index 135 15.3 ± 1.2 0.0–60.0 4.0 11.0 25.0
ER expressionc 147 1.2 ± 0.1 0.0–3.0 0.0 1.0 2.2
PR expressionc 146 0.8 ± 0.1 0.0–3.0 0.0 0.1 1.6
DFS (months) 124 35.9 ± 0.9 3.8–47.2 33.4 39.5 43.1
a Standard error
b Relative quantification units = 2-DDCT
c Immunohistochemical score (Hscore)
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Quantitative real-time PCR (RT-qPCR)
The quantification of KLK8 mRNA expression levels was
performed by RT-qPCR, using the SYBR Green chemistry
on a 7500 fast real-time PCR system (Applied Biosystems).
Gene-specific primer pairs were designed based on the
published cDNA sequences of the reference gene HPRT1
(NM_000194.2), and the KLK8 type 1 mRNA transcript
variant, which encodes the canonical 260-amino acid KLK8
protein (NM_007196.3). The primer sequences used in this
study were as follows: KLK8 forward 50-GGAGCCTGGG
CAGGACAC-30 and reverse 50-AAGGACACCGCCACAG
AGTAGTT-30 (PCR amplicon of 129 bp); HPRT1 forward
50-TGGAAAGGGTGTTTATTCCTCAT-30 and reverse 50-
ATGTAATCCAGCAGGTCAGCAA-30 (PCR amplicon of
151 bp). We selected HPRT1 as a housekeeping gene for
data normalization as it was previously identified as the most
suitable single endogenous control gene for expression
studies in various solid tumors, including BC [27].
The RT-qPCR reaction mixture consisted of 10 ng of
template cDNA, 5.0 lL Kapa SYBR fast qPCR Master Mix
(Kapa Biosystems), 0.2 lL of 509 Rox low passive refer-
ence dye (Kapa Biosystems), 1.0 lL of gene-specific pri-
mers (final concentrationKLK8: 350 nM;HPRT1: 300 nM),
adjusted to a final volume of 10.0 lL with DEPC-treated
water. All genes were amplified in technical triplicates for
each sample, using the following thermal cycling conditions:
an initial step at 95 C for 3 min, followed by 40 cycles of
95 C for 15 s and 60 C for 1 min. After the completion of
RT-qPCR cycles, melting curves of amplified products were
generated in order to verify the reaction specificity and the
absence of primer dimers and/or contamination. In addition,
randomly selected RT-qPCR products were electrophoresed
on 3.0 % (w/v) agarose gel and visualized, under UV light,
after ethidium bromide staining.
The relative quantification ofKLK8mRNAexpressionwas
performed using the comparative threshold cycle (DDCt)
method. Relative quantification units (RQ units) of KLK8 in
each sample were calculated based on the equation:
RQ units = 2-DDCt. TheDCt is the difference between the Ct
value of the target gene and the endogenous control
[DCt = Ct (KLK8) - Ct (HPRT1)] and DDCt is the differ-
ence between the average DCt value of an experimental
sample and the average DCt of the corresponding calibrator
[DDCt = DCt (sample) - DCt (calibrator)] [28]. In the cur-
rent study, the human BC cell line BT-474 served as a
calibrator.
The main requirement for the application of the com-
parative Ct method is that the amplification efficiencies of
the target and reference genes are approximately equal and
close to 100 %. Therefore, validation experiments were
carried out using a tenfold dilution series of calibrator
cDNA, covering several orders of magnitude, for the
generation of standard curves by plotting Ct values vs log
of input cDNA. The RT-qPCR efficiency (E) was calcu-
lated from the slope of the standard curves according to the
formula: E = (10(-1/slope) - 1) 9 100.
Statistical analyses
The KLK8 expression data and patients’ clinicopathologi-
cal characteristics were subjected to extensive biostatistical
analyses using the SPSS software program (SPSS Inc.,
version 17.0). The nonparametric Wilcoxon signed-ranks
test was applied to analyze the differences of KLK8 mRNA
expression in the pairs of matched non-cancerous and
tumor counterparts. We also used the Oncomine database
[29] to determine whether KLK8 mRNA expression is
deregulated in clinical BC samples compared to non-
cancerous breast tissues, based on microarray gene
expression profiling studies employing established patient
datasets. Moreover, the correlations between continuous
variables of the study were examined with Spearman cor-
relation coefficient (rs). The Mann–Whitney U, Jonck-
heere–Terpstra, and Kruskal–Wallis tests were employed
to scrutinize the differences of KLK8 expression between
distinct groups of BC samples. The capability of KLK8
levels to distinguish triple negative breast tumors (TNBC)
from other molecular BC subtypes was evaluated via the
construction of Receiver operating characteristic (ROC)
curve, by plotting sensitivity versus (1-specificity) values.
The area under the curve (AUC) was analyzed using the
Hanley and McNeil method.
We also applied the X-tile algorithm [30] in order to
dichotomize BC patients into KLK8-low and KLK8-high
expression populations. X-tile plots allowed the determi-
nation of an optimal cutoff value for KLK8 expression data
based on DFS, while correcting for the use of minimum
P value statistics. Corrected P values for the cutoff points
were calculated using the Miller–Siegmund P value cor-
rection and Monte Carlo simulations (e.g., Cross-valida-
tion) based on 1000 random populations. The software also
splits the entire population cohort into random training and
validation subsets, and subsequently finds the appropriate
cutoff in the training set and then applies this cut-point in
the validation cohort, allowing in this way the internal
validation of the results. The cutoff point calculated by the
above-mentioned approaches was defined as 4.68 RQ units
of KLK8 expression (69th percentile). KLK8 mRNA
expression was also analyzed as a continuous variable in
order to minimize the loss of information due to catego-
rization. Survival analysis was done by constructing
Kaplan–Meier DFS curves and significance was evaluated
using the log-rank test. Both univariate and multivariate
Cox proportional hazard regression models were developed
in order to determine the prognostic value, with respect to
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DFS, of KLK8 expression and other clinical parameters.
The multivariate regression model was adjusted for estab-
lished clinicopathological and demographic variables
including TNM stage, lymph node status, histological
grade, BC molecular subtype, and patients’ age. Moreover,
we developed a separate multivariate model which inclu-
ded KLK8 expression and the different adjuvant treatment
modalities used (chemotherapy and endocrine therapy).
We next performed a complementary statistical approach,
in order to analyze the prognostic value of KLK8 mRNA
expression in subgroups of patients, stratified according to
the type of systemic adjuvant treatment received. Thereafter,
Kaplan–Meier survival analysis was done for each patient
subgroup (i.e., adjuvant chemotherapy-treated, no
chemotherapy-treated, adjuvant endocrine-treated, and no
endocrine-treated). A P value of less than 0.05 was consid-
ered as an indication of statistical significance.
Results
Quality control of the RT-qPCR assay
for the quantification of KLK8 mRNA expression
Gene-specific amplification was confirmed by the presence
of a single peak with the appropriate melting point tem-
perature (Tm) for each amplicon (KLK8 Tm = 86.3 C;
HPRT1 Tm = 81.5 C) (Supplementary Fig. 1A and B)
and by the appearance of a single band, of the expected
amplicon size, in the agarose gel electrophoresis analyses
(Supplementary Fig. 1C).
The RT-qPCR amplification efficiencies for the refer-
ence and target gene were calculated from the slopes of the
corresponding standard curves deriving from validation
experiments. The slopes of HPRT1 (-3.344; R2 = 0.999)
and KLK8 (-3.402 0; R2 = 0.996) standard curves were
similar (Supplementary Fig. 1D), and the calculated PCR
amplification efficiencies were 99.0 and 96.7 % corre-
spondingly, thereby allowing relative quantification by the
application of the 2-DDCt formula.
Downregulation of KLK8 mRNA expression
in cancerous compared to matched histologically
normal breast tissues
The expression of KLK8 was investigated in 100 paired
specimens of cancerous and matched histologically normal
breast tissues located adjacent to the carcinoma. This
analysis revealed that KLK8 mRNA expression levels were
significantly downregulated in BC tissue sections com-
pared to the non-cancerous component in 72 % of the cases
examined, whereas only 28 % of the paired samples
exhibited higher KLK8 expression in the cancerous part
than their corresponding non-tumor breast tissues
(P\ 0.001; Wilcoxon signed-ranks test; Fig. 1a).
Using the oncomine database, we observed that KLK8
expression levels were substantially downregulated in the
majority of BCs of different subtypes, relative to non-
malignant breast tissues (Fig. 1b).
KLK8 mRNA expression is associated
with advanced TNM stage, lymph node positive
status, and triple negative breast tumors (TNBC)
In the next step of our study, we investigated the associa-
tions between KLK8 mRNA expression levels in BC tissues
with the clinicopathological parameters of the patients
examined. Our data showed that KLK8 expression is
Fig. 1 The mRNA expression of KLK8 is frequently decreased in
human BC tissues. a Bar graph representing the relative expression
levels of KLK8 in 100-paired BC specimens and matched adjacent
non-cancerous tissues. Data are presented as the ratio of KLK8
expression in cancerous tissue part versus non-cancerous counterpart.
The P value was calculated using ‘‘Wilcoxon signed-ranks test’’.
b Studies from Oncomine database showing significant downregula-
tion of KLK8 levels in breast carcinomas vs normal analyses
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associated with several clinicopathological features, indica-
tive of unfavorable prognosis in BC patients (Table 2). In
particular, KLK8 mRNA expression levels had an increasing
trend with the progression of the tumor TNM stage
(P = 0.019) (Fig. 2a). The median KLK8 expression in the
group of patients with clinical stage III or IV (5.18 RQ units)
was remarkably higher compared to TNM stage II (2.31 RQ
units), and stage I or 0 (2.16 RQ units) tumors. Furthermore,
a significant positive relationship between KLK8 expression
with positive nodal status was also observed (P = 0.044).
KLK8mRNAexpression differed remarkably (P = 0.002;
Kruskal–Wallis Test) between BC molecular subtypes
(Fig. 2b). Moreover, KLK8 mRNA expression was found to
be significantly increased (P = 0.009) in the group of patients
with TNBC (median 3.85RQunits) tumors compared to those
with other BC molecular subtypes (median 1.64 RQ units).
ROC curve analysis revealed the ability of KLK8 mRNA
expression to distinguish patients with TNBC from patients
harboring breast tumors of other molecular subtypes
([AUC] = 0.653, [95 % CI] = 0.546–0.760, P = 0.009)
(Fig. 2d). High KLK8 levels were also found in TNBC and
HER2 overexpressing groups (collectively non-luminal sub-
types) compared to luminal A and B (luminal subtypes) ones
(P\ 0.001) (Fig. 2c). The median KLK8 expression in the
group of patients with non-luminal BC subtypes (4.47 RQ
units) was substantially higher compared to luminal (1.59 RQ
units) carcinomas.
On the contrary, no significant association was found
between KLK8 expression and tumor grade, HER2 status,
Ki67 proliferative index, or patients’ age.
Table 2 Associations of KLK8
mRNA expression with
clinicopathological data of BC
patients
Variable No. of patients Mean ± SEa Median P value
TNM stageb
0 or I 34 6.8 ± 3.3 2.16 0.019d
II 85 10.8 ± 3.1 2.31
III or IV 25 11.6 ± 3.4 5.18
Molecular subtype
Luminal A 47 5.9 ± 2.4 1.24 0.002e
Luminal B 42 4.9 ± 1.6 1.80
HER2 group 14 23.6 ± 13.1 5.74
TNBC 32 16.7 ± 5.8 3.85
Molecular subtype
Luminal A and B (luminal subtypes) 89 5.5 ± 1.5 1.59 <0.001f
TNBC and HER2 (non-luminal subtypes) 46 18.8 ± 5.6 4.47
Lymph node status
N0 or N1 123 9.6 ± 2.3 2.32 0.044f
N2 or N3 18 11.1 ± 3.5 5.52
Histological gradec
Grade I or II 96 8.2 ± 2.3 1.94 0.253f
Grade III 50 13.5 ± 3.9 2.77
HER2 status
Negative 104 8.3 ± 1.9 2.43 0.209f
Positive 41 14.4 ± 5.3 2.82
Ki67 labeling index
Negative 77 8.8 ± 2.9 2.55 0.650f
Positive 58 8.7 ± 2.3 2.52
Age (years)
\60 80 6.9 ± 1.4 2.55
C60 69 13.1 ± 4.0 2.33 0.790f
a Standard error
b TNM staging system
c Bloom–Scarff–Richardson grading system
d Calculated using the ‘‘Jonckheere–Terpstra test’’
e Calculated by the ‘‘Kruskal–Wallis test’’
f Calculated by the ‘‘Mann–Whitney U test’’
Bold value indicates statistical significance
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Using the Spearman correlation coefficient analysis we
also observed a weak negative correlation between KLK8
mRNA levels and ER (rs = -0.281; P = 0.001) and PR
(rs = -0.273; P = 0.001) expression, in breast tumors. No
correlations were observed between KLK8 expression and
other continuous variables such as tumor size, patients’
age, and Ki67 labeling index.
Internal validation of the prognostic significance
of KLK8 based on an optimal cutoff value
The X-tile algorithm generated an optimal cutoff value
equal to the 69th percentile (4.68 RQ units) of KLK8
expression that was able to effectively dichotomize our
patient cohort based on DFS analysis, while correcting the
chance of type I errors (Miller–Siegmund P\ 0.001). The
significance of the selected cutoff point was reinforced by
Monte Carlo simulations based on 1000 random popula-
tions (Cross-validation P = 0.0010, Monte Carlo corrected
P\ 0.001). Moreover, the patients’ cohort was randomly
divided into training and validation subsets (2:1 patient
population ratio), in order to perform internal validation.
The above-mentioned selected cutoff was identified as
optimal in the training cohort (P = 0.0012), and after its
application in the validation cohort it also reached high
statistical significance (P = 0.014).
KLK8 expression is associated with poor DFS of BC
patients
Next, we aimed to investigate the possible prognostic value
of KLK8 expression status in the entire BC patients’ cohort.
Fig. 2 Association of KLK8 mRNA expression with clinicopatho-
logical features of breast tumors. Boxplots representing KLK8
expression levels in early vs advanced TNM stage tumors (a), in
distinct BC molecular subtypes (b) and in luminal vs non-luminal
disease (c). ROC curve analysis revealed the ability of KLK8 mRNA
expression to distinguish patients with TNBC from patients harboring
breast tumors of other molecular subtypes (d)
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For this purpose, we initially performed Kaplan–Meier
DFS curve analysis with log-rank test for determining
statistical significance. Notably, patients with BC belong-
ing to the KLK8-high expression group had significantly
(P\ 0.001) shorter DFS intervals compared to patients in
the KLK8–low expression group (Fig. 3). The 3-year
cumulative probability of BC-specific DFS for patients
belonging to the KLK8-high group was 0.561 whereas the
corresponding probability for patients in the KLK8-low
group was 0.931.
Using univariate Cox regression analysis, we further
confirmed the unfavorable prognostic value of KLK8
expression, with respect to DFS, in BC patients. Firstly,
analysis was performed using KLK8 mRNA expression as a
continuous variable (log-transformed values of RQ units).
As shown in Table 3, the risk of relapse was significantly
associated with KLK8 mRNA expression (hazard ratio
[HR] = 3.28, 95 % confidence interval [95 %
CI] = 1.92–5.61, P\ 0.001). Moreover, BC patients
belonging in the KLK8-high expression group had a signif-
icantly higher risk of relapse ([HR] = 6.55, [95 %
CI] = 2.66–16.15, P\ 0.001) over time, compared to
patients in the KLK8-low expression group.
Additional clinicopathological variables, including clinical
TNM stage, BC molecular subtype, tumor size, and lymph
node statuswere also strongly associatedwith poorDFSofBC
patients (All HR[1.0, and P values\0.05; Table 3).
KLK8 expression is an independent predictor
of unfavorable prognosis in BC patients
The independence of KLK8 expression in predicting unfa-
vorable outcome in BC patients was also evaluated using
Cox multivariate analysis. In particular, after adjustment for
important clinicopathological factors including TNM stage,
nodal status, BC molecular subtype, histological grade, and
patients’ age, KLK8 mRNA expression, as a continuous
variable, was found to be a strong independent predictor of
adverse prognosis for BC patients with a hazard ratio of 2.69
([95 % CI] = 1.42–5.12, P = 0.003). Moreover, we repe-
ated the analysis described above using KLK8 expression as
a binary variable. Again, high-KLK8 expression retained its
independent unfavorable prognostic nature with a hazard
ratio 4.54 ([95 % CI] = 1.64–12.57, P = 0.004) (Table 4).
Moreover, a separate multivariate model which included
KLK8 mRNA expression and the different adjuvant treat-
ment modalities (chemotherapy; endocrine therapy) was
developed. Interestingly, after correcting for adjuvant treat-
ment, KLK8 mRNA expression retained its independence as
an indicator of unfavorable outcome for BC patients
([HR] = 2.00, [95 % CI] = 1.08–3.73, P = 0.029). The
same conclusions were drawn when KLK8 mRNA expres-
sion was used as a dichotomous variable ([HR] = 3.31,
[95 % CI] = 1.22–8.98, P = 0.019).
KLK8 mRNA expression is associated
with unfavorable DFS in subgroups of BC patients,
stratified according to the type of adjuvant systemic
therapy received
In order to evaluate the prognostic relevance ofKLK8mRNA
expression regarding DFS in subgroups of patients based on
the adjuvant systemic therapy received, a stratified Kaplan–
Meier survival curve analysis was performed. In both, adju-
vant chemotherapy-treated and endocrine-treated subgroups,
patients with high-KLK8 mRNA expression presented a sig-
nificantly shorter DFS (chemotherapy-treated P = 0.003;
endocrine-treatedP = 0.001), compared to those categorized
as KLK8-low. In patients who had not received adjuvant
chemotherapy, high-KLK8 was also associated with shorter
DFS intervals reaching statistical significance (P = 0.016).
However, in the subgroup of patients who did not receive
adjuvant endocrine treatment, no impact of KLK8 expression
status on DFS was observed (P = 0.204) (Fig. 4).
Discussion
In the present study we quantitatively analyzed KLK8
mRNA expression in breast tumors and matched histo-
logically normal tissue sections, in order to investigate the
Fig. 3 Kaplan–Meier disease-free survival curve for the whole
cohort of 124 BC patients. Patients were categorized as KLK8-high
or KLK8-low expression groups according to the optimal cutoff value
(69th percentile). P value was calculated via the log-rank algorithm
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possible associations with clinicopathological features of
the patients, and to further assess its prognostic perfor-
mance in BC with respect to prediction of disease pro-
gression. To the best of our knowledge, this is the first
study examining the clinical relevance of KLK8 mRNA
expression, in breast carcinomas.
Our data demonstrate that KLK8 expression levels are
significantly (P\ 0.001) downregulated in BC tissue parts
compared to adjacent histologically normal counterparts in
the majority (72 %) of paired breast specimens examined.
We next performed in silico expression analysis using
information from the Oncomine expression profiling
database, which revealed that KLK8 mRNA expression is
markedly decreased in breast carcinomas than in normal
breast tissues, corroborating our findings. These observa-
tions are in agreement with previous studies showing that
most of the KLK family members, including KLK8, exhibit
reduced mRNA and/or protein expression levels in breast
tumors compared to non-malignant breast tissues [21, 22,
31]. In particular, Yousef et al., using a small set of BC and
normal tissues showed that KLK8 mRNA levels were lower
in tumors than in non-cancerous breast tissues [22]. A
recent study using massively parallel signature sequencing
(MPSS) and isolated epithelial cells from BC and normal
Table 3 Cox univariate
regression analysis of KLK8
expression and
clinicopathological variables for
the prediction of disease-free
survival (DFS)
Variable No. of patients Univariate analysis
HRa 95 % CIb P value
KLK8 expression
Log10 (KLK8 RQ units) 124 3.28 1.92–5.61 <0.001
Negative 87 1.00
Positive 37 6.55 2.66–16.15 <0.001
TNM stage
0/I/II 102 1.00
III/IV 19 4.99 2.04–12.26 <0.001
Lymph node status
N0/N1 104 1.00
N2/N3 15 3.85 1.47–10.02 0.006
Molecular subtype
Luminal A or B 81 1.00
TNBC or HER2 group 38 3.74 1.59–8.76 0.002
Grade
I/II 81 1.00
III 42 0.76 0.29–1.95 0.571
HER2 status
Negative 89 1.00
Positive 34 1.87 0.79–4.37 0.150
Ki67 labeling index
Negative 70 1.00
Positive 46 0.67 0.26–1.74 0.412
CEA
Negative 90 1.00
Positive 8 1.73 0.39–7.61 0.469
Tumor size (ordinal) 119 1.41 1.13–1.76 0.003
Age (ordinal) 124 1.02 0.98–1.05 0.228
Adjuvant chemotherapy
No 24 1.00
Yes 93 1.35 0.38–4.65 0.639
Adjuvant endocrine therapy
No 47 1.00
Yes 70 0.16 0.05–0.48 0.001
a Hazard ratio, estimated from Cox proportional hazard regression model
b Confidence interval of the estimated HR
Bold value indicates statistical significance
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counterparts revealed that KLK8, along with KLK5, KLK7,
KLK10, is among the set of genes which are significantly
downregulated in the tumor epithelial transcriptome
[32]. Several reports show that molecular mechanisms,
such as epigenetic modifications and specifically DNA
hypermethylation, may contribute to the downregulation of
KLK gene expression in BC [33]. One characteristic
example is the tumor-specific KLK10 exon 3 hyperme-
thylation in BC cell lines and tissues [34, 35]. Therefore,
we may speculate that changes in DNA methylation could
Table 4 Cox multivariate
analysis of KLK8 expression
regarding disease-free
survival (DFS)
Variable No. of patients Multivariate analysis
HRa 95 % CIb P value
KLK8 expressionc
Log10 (KLK8 RQ units) 115 2.69 1.42–5.12 0.003
TNM stage
0/I/II 97 1.00
III/IV 18 7.78 1.61–37.54 0.011
Lymph node status
N0/N1 100 1.00
N2/N3 15 0.68 0.13–3.48 0.642
Molecular subtype
Luminal A or B 78 1.00
TNBC or HER2 group 37 3.66 1.25–10.69 0.018
Grade
I/II 75 1.00
III 40 0.41 0.13–1.24 0.114
Age (ordinal) 115 1.03 0.99–1.08 0.168
KLK8 expressionc
Negative 82 1.00
Positive 33 4.54 1.64–12.57 0.004
TNM stage
0/I/II 97 1.00
III/IV 18 6.99 1.55–31.61 0.012
Lymph node status
N0/N1 100 1.00
N2/N3 15 0.54 0.11–2.64 0.446
Molecular subtype
Luminal A or B 78 1.00
TNBC or HER2 group 37 4.45 1.58–12.54 0.005
Grade
I/II 75 1.00
III 40 0.38 0.13–1.18 0.096
Age (ordinal) 115 1.04 1.00–1.09 0.046
KLK8 expressiond
Log10 (KLK8 RQ units) 117 2.00 1.08–3.73 0.029
KLK8 expressiond
Negative 85 1.00
Positive 32 3.31 1.22–8.98 0.019
a Hazard ratio, estimated from Cox proportional hazard regression model
b Confidence interval of the estimated HR
c Multivariate models were adjusted for TNM stage, histological grade, nodal status, BC molecular sub-
type, and patients’ age
d Multivariate models were adjusted for adjuvant treatment modalities (chemotherapy and endocrine
therapy)
Bold value indicates statistical significance
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partially account for the deregulation of KLK8 expression
in breast tumors.
According to our data, KLK8 mRNA expression was
found to be associated with important indicators of poor
prognosis in BC and with more aggressive forms of the
disease. In more details, KLK8 mRNA levels were
increased in a statistically significant degree (P = 0.019) in
the group of patients with advanced TNM stage (III/IV)
compared to those with TNM stage II or I breast tumors. In
addition, KLK8 expression was found to be associated with
Fig. 4 Kaplan–Meier disease-free survival analyses for BC patient subgroups. Adjuvant chemotherapy-treated (a), no adjuvant chemotherapy-
treated (b), adjuvant endocrine-treated (c), and no adjuvant endocrine-treated (d). P values were calculated via the log-rank algorithm
Breast Cancer Res Treat (2015) 152:323–336 333
123
positive nodal status of the patients (P = 0.044). We also
observed a weak negative correlation between KLK8 and
ER (rs = -0.281; P = 0.001) and PR (rs = -0.273;
P = 0.001) levels of expression.
Another important finding of our present research was
the remarkable higher expression levels of KLK8 in TNBC,
compared to other molecular subtypes of disease. The
differential diagnostic potential of this observation was
also demonstrated by ROC curve analysis (AUC = 0.653;
P = 0.009). Interestingly, mRNA expression of KLK8 was
significantly (P\ 0.001) higher in non-luminal breast
carcinomas (TNBC and HER2 overexpressing tumors) than
luminal subtypes (luminal A and B) of BC. Generally, non-
luminal BC molecular subtypes, and particularly TNBC,
are associated with worse overall and disease-free survival
rates compared to luminal disease [36–38]. Therefore, it is
tentative to say that KLK8 expression may be used in
conjunction with established molecular markers in order to
refine BC molecular classification and to improve treat-
ment selection for individual patients. Supporting this
hypothesis, the basal-like group of tumors, which typically
lack or show low levels of hormone receptors and HER2
expression [38], exhibit high expression of a unique cluster
of genes that are usually found in the basal epithelial cell
layer. These include among others keratins 5, 6, and 17 and
four KLKs, including KLK8 [39]. Additionally, Glynn
et al., using microdissected BC epithelium from high nitric
oxide synthase ER-negative tumors also showed that KLK8
was among the basal-like signature genes [40]. Further-
more, given on the one hand the recognition that gene
expression signatures have the potential to identify
molecular changes that can be used to predict recurrence of
disease as well as response to specific therapies and on the
other, the rapid rise in interest in developing multigene
prognostic and predictive tools, such as real-time PCR-
based assays (e.g., Oncotype DX and PAM50) and
microarray-based multigene tests (e.g., MammaPrint) [41],
one might consider the inclusion of KLK8 into multifac-
torial biomarker panels and/or other multigene assays that
may contribute in the multidimensional approach which is
required for optimal management of BC patients. Inter-
estingly, data from a ‘‘four-kallikrein panel’’ are very
encouraging for prostate cancer patients’ management and
several multicomponent KLK-based panels have been
described for other cancers as well (e.g., ovarian and lung
cancer) [15].
According to Kaplan–Meier survival curve analysis,
after internal validation, patients belonging to the KLK8-
high expression group had significantly (P\ 0.001) shorter
DFS intervals, compared to patients in the KLK8–low
expression group. Cox univariate regression analysis
confirmed the significantly poorer DFS of patients with
high-KLK8 expression, analyzed as a continuous variable
([HR] = 3.28, P\ 0.001). Although these results seem to
be contradictory with the observed downregulation of
KLK8 mRNA expression in BC tissues compared to his-
tologically normal counterparts, this phenomenon is, in
fact, common and it was previously reported for other KLK
family members in BC studies. For instance KLK5, KLK7,
and KLK14 are all reported to be downregulated in the BC
tissues relative to non-cancerous ones. However, the
expression of these KLKs has been associated with poor
prognosis of BC patients [42–44]. The question that
remains is how these KLKs are associated with BC pro-
gression, since their mRNA levels appear to be downreg-
ulated in BC tissues. One possible explanation is that KLK
mRNA expression levels might not correlate with protein
expression levels in BC tissues, due to a regulation on the
translational level [22]. Another possible explanation
comes from a microarray study by Tripathi et al., which
showed that global gene expression abnormalities occur in
normal epithelium of BC patients [45]. Interestingly,
Schummer et al., revealed that a number of genes, usually
associated with cancer pathways, are expressed at lower
levels in BC compared to normal breast tissue [46]. Fur-
thermore, growing evidence suggests, that primary tumor
growth induces molecular changes in adjacent tissues that
are believed to support cancer progression [47].
Multivariate Cox regression model adjusted for impor-
tant clinicopathological parameters such as TNM stage,
nodal status, BC molecular subtype, patients’ age, and
histological grade, identified KLK8 expression ([HR] =
2.69, P = 0.003) as a strong and independent indicator of
unfavorable outcome with regard to DFS, for BC patients.
Most importantly, KLK8 mRNA expression retained its
independence as an indicator of poor DFS for BC patients
([HR] = 2.00, P = 0.029), irrespective of the post-opera-
tive therapeutic modalities used. It should be noted here
that KLK8 protein expression was previously identified as
a predictor of adverse progression-free survival in patients
with advanced ovarian cancer [18], while KLK8 type 4
splice variant is an independent indicator of poor OS in
lung cancer patients [20].
Despite performing internal validation, a more rigorous
verification of our observations through external validation
on heterogeneous, larger, and multicentric datasets, is
among our future goals in order to strengthen the signifi-
cance of our findings and to confirm KLK8 significance as a
BC biomarker. Another interesting future perspective
would be the assessment of KLK8 protein expression in
bodily fluids, such as nipple aspirate fluid or serum from
BC patients, and its clinical evaluation as a soluble bio-
marker for non-invasive diagnosis, prognosis, and predic-
tion or monitoring of chemotherapy response in BC.
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Conclusions
Our study is the first to show that high-KLK8 mRNA levels
are significantly associated with advanced TNM stage,
non-luminal (TNBC and HER2 overexpressing) molecular
subtypes of BC, and with poor clinical outcome, in terms of
DFS, of BC patients. Most importantly we show that KLK8
expression is an independent indicator of unfavorable
outcome for BC patients.
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